Special Issue "Pathogenesis of Non-alcoholic Steatohepatitis (NASH)-Related Hepatocellular Carcinoma (HCC)"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 1 February 2024 | Viewed by 188

Special Issue Editor

Dr. Kathryn Effendi
E-Mail Website
Guest Editor
Department of Pathology, Keio University School of Medicine, Tokyo, Japan
Interests: hepatocellular carcinoma (HCC); early HCC; metabolic associated fatty liver disease (MAFLD); NASH; HCC tumor markers; liver pathology

Special Issue Information

Dear Colleagues,

The prevalence of hepatocellular carcinoma (HCC) associated with non-alcoholic fatty liver disease (NAFLD) and NASH is increasing worldwide. NASH is expected to become a leading cause of HCC, replacing viral hepatitis-associated HCC. Several factors including genetic and external lifestyle factors contribute to the progression of NASH into HCC, and the presence of metabolic syndrome has also been linked to this process as risk factors flare up the liver damage. More efforts to implement effective management in NAFLD/NASH-related HCC are needed to overcome its future impact.

The purpose of this Special Issue is to understand current mechanism of the complex pathogenesis and progression of NASH-related HCC in multidisciplinary approaches. Potential submissions may focus on (1) early prediction for those at risk of HCC; (2) pathological markers, or inflammatory process mediating the progression of NASH; (3) preventive strategies that can modulate carcinogenic pathways in NAFLD/NASH-related HCC.

For this Special Issue we welcome reviews, as well as original research articles, until 01 February 2024. We look forward to receiving your contributions.

Dr. Kathryn Effendi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • non-alcoholic fatty liver disease
  • metabolic syndrome
  • fibrosis
  • chronic inflammation
  • biomarkers
  • pathogenesis
  • immune microenvironment

Published Papers

This special issue is now open for submission.
Back to TopTop